We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

By LabMedica International staff writers
Posted on 13 Mar 2024
Print article
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative disease assays. Both companies entered into a collaboration agreement in 2023 to target new biomarkers in line with the recently approved monoclonal antibody-based Alzheimer’s disease therapeutics. These new drugs have demonstrated a major impact on slowing disease progression and improving patients' health. The companies have now extended this research program and further refined the target analytes, including a pTau217 plasma assay being developed by Beckman Coulter and a Beta Amyloid 1-42 plasma assay under development by Fujirebio.

These new assays are being developed for use on the recently launched DxI 9000 Immunoassay Analyzer from Beckman Coulter. The DxI 9000 Analyzer’s novel Lumi-Phos PRO Substrate has demonstrated the ability to develop highly sensitive and clinically relevant assays. This agreement leverages Fujirebio’s expertise in the development, manufacturing and regulatory registration of its Neurological Reagent Kits and its wide Neurological Biomarker menu. Fujirebio currently offers a full range of research use only (RUO) blood-based neurodegenerative biomarkers including β-amyloid1-42, β-amyloid1-40, phospho-Tau181, neurofilament light (NfL), ApoE4, Pan-ApoE and phospho-Tau217.

“We are very excited by our expanded partnership with Fujirebio designed to overcome challenges of developing highly sensitive assays, measuring ultra-low concentrations of neurodegenerative disease biomarkers circulating in the bloodstream,” said Kevin O’Reilly, President, Beckman Coulter Diagnostics.

“Our expanded partnership with Beckman Coulter will enable increased laboratory, clinician and patient access to more neurodegenerative biomarkers around the world,” added Monte Wiltse, President & CEO, Fujirebio Diagnostics, Inc. “We look forward to continued collaboration with Beckman Coulter bringing these critical assays to physicians and patients worldwide.”

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Troponin I Test
Quidel Triage Troponin I Test
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: Microscopic images showing healthy villi on the left and diseased villi on the right (Photo courtesy of Florian Jaeckle/University of Cambridge)

Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy

Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.